- Home
- CMII vs FENC Comparison
CMII vs FENC Comparison
Compare CMII & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$6.43
Company Overview
Basic Information| Metric | CMII | FENC |
|---|---|---|
| Founded | 2025 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.6M | 266.4M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | CMII | FENC |
|---|---|---|
| Price | $9.86 | $6.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 28.8K | ★ 221.0K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $69.68 |
| Revenue Next Year | N/A | $37.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.76 | $5.02 |
| 52 Week High | $9.95 | $9.92 |
Technical Indicators
Market Signals| Indicator | CMII | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 44.19 |
| Support Level | $9.83 | $5.65 |
| Resistance Level | $9.95 | $8.09 |
| Average True Range (ATR) | 0.02 | 0.38 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 30.77 | 69.61 |
Price Performance
Historical Comparison CMII
FENC
About CMII Columbus Circle Capital Corp II Class A Ordinary Shares
Columbus Circle Capital Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.